PMID- 26646032
OWN - NLM
STAT- MEDLINE
DCOM- 20160329
LR  - 20211118
IS  - 1555-2101 (Electronic)
IS  - 0160-6689 (Print)
IS  - 0160-6689 (Linking)
VI  - 76
IP  - 11
DP  - 2015 Nov
TI  - Inflammatory markers among adolescents and young adults with bipolar spectrum 
      disorders.
PG  - 1556-63
LID - 10.4088/JCP.14m09395 [doi]
AB  - OBJECTIVE: Despite burgeoning literature in middle-aged adults, little is known 
      regarding proinflammatory markers (PIMs) among adolescents and young adults with 
      bipolar disorder. Similarly, few prior studies have considered potential 
      confounds when examining the association between PIMs and bipolar disorder 
      characteristics. We therefore retrospectively examined these topics in the Course 
      and Outcome of Bipolar Youth (COBY) study. METHOD: Subjects were 123 adolescents 
      and young adults (mean [SD] = 20.4 +/- 3.8 years; range, 13.4-28.3 years) in COBY, 
      enrolled between October 2000 and July 2006. DSM-IV diagnoses were determined 
      using the Schedule for Affective Disorders and Schizophrenia for School-Age 
      Children (K-SADS). Clinical characteristics during the preceding 6 months, 
      including mood, comorbidity, and treatment, were evaluated using the Longitudinal 
      Interval Follow-Up Evaluation (LIFE). Serum levels of interleukin (IL)-6, tumor 
      necrosis factor (TNF)-alpha, and high-sensitivity C-reactive protein (hsCRP) were 
      assayed. Primary analyses examined the association of PIMs with bipolar disorder 
      characteristics during the preceding 6 months. RESULTS: Several lifetime clinical 
      characteristics were significantly associated with PIMs in multivariable 
      analyses, including longer illness duration (P = .005 for IL-6; P = .0004 for 
      hsCRP), suicide attempts (P = .01 for TNF-alpha), family history of suicide attempts 
      or completion (P = .01 for hsCRP), self-injurious behavior (P =.005 for TNF-alpha), 
      substance use disorder (SUD) (P < .0001 for hsCRP), and family history of SUD (P 
      = .02 for TNF-alpha; P = .01 for IL-6). The following bipolar disorder 
      characteristics during the preceding 6 months remained significantly associated 
      with PIMs in multivariable analyses that controlled for differences in 
      comorbidity and treatment: for TNF-alpha, percentage of weeks with psychosis (chi(2) = 
      5.7, P =.02); for IL-6, percentage of weeks with subthreshold mood symptoms 
      (chi(2)= 8.3, P = .004) and any suicide attempt (chi(2) = 6.1, P = .01); for hsCRP, 
      maximum severity of depressive symptoms (chi(2) = 8.3, P =.004). CONCLUSION: 
      Proinflammatory markers may be relevant to bipolar disorder characteristics as 
      well as other clinical characteristics among adolescents and young adults with 
      bipolar disorder. Traction toward validating PIMs as clinically relevant 
      biomarkers in bipolar disorder will require repeated measures of PIMs and 
      incorporation of relevant covariates.
CI  - (c) Copyright 2015 Physicians Postgraduate Press, Inc.
FAU - Goldstein, Benjamin I
AU  - Goldstein BI
AD  - Department of Psychiatry, Sunnybrook Health Sciences Centre, 2075 Bayview Ave, 
      FG53, Toronto, Ontario, M4N-3M5 Benjamin.Goldstein@sunnybrook.ca.
FAU - Lotrich, Francis
AU  - Lotrich F
FAU - Axelson, David A
AU  - Axelson DA
FAU - Gill, Mary Kay
AU  - Gill MK
FAU - Hower, Heather
AU  - Hower H
FAU - Goldstein, Tina R
AU  - Goldstein TR
FAU - Fan, Jieyu
AU  - Fan J
FAU - Yen, Shirley
AU  - Yen S
FAU - Diler, Rasim
AU  - Diler R
FAU - Dickstein, Daniel
AU  - Dickstein D
FAU - Strober, Michael A
AU  - Strober MA
FAU - Iyengar, Satish
AU  - Iyengar S
FAU - Ryan, Neal D
AU  - Ryan ND
FAU - Keller, Martin B
AU  - Keller MB
FAU - Birmaher, Boris
AU  - Birmaher B
LA  - eng
GR  - R01 MH059691/MH/NIMH NIH HHS/United States
GR  - MH59691/MH/NIMH NIH HHS/United States
GR  - MH59977/MH/NIMH NIH HHS/United States
GR  - R01 MH112543/MH/NIMH NIH HHS/United States
GR  - R01 MH059977/MH/NIMH NIH HHS/United States
GR  - MH059929/MH/NIMH NIH HHS/United States
GR  - R01 MH059929/MH/NIMH NIH HHS/United States
GR  - CAPMC/CIHR/Canada
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Clin Psychiatry
JT  - The Journal of clinical psychiatry
JID - 7801243
RN  - 0 (Biomarkers)
RN  - 0 (Interleukin-6)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 9007-41-4 (C-Reactive Protein)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Biomarkers/blood
MH  - Bipolar Disorder/*blood
MH  - C-Reactive Protein/*analysis
MH  - Female
MH  - Humans
MH  - Inflammation/*blood
MH  - Interleukin-6/*blood
MH  - Male
MH  - Retrospective Studies
MH  - Tumor Necrosis Factor-alpha/*blood
MH  - Young Adult
PMC - PMC4896394
MID - NIHMS790623
COIS- FINANCIAL DISCLOSURES Disclosure: Gill, Hower, and Sorioso report no biomedical 
      financial interests or potential conflicts of interest.
EDAT- 2015/12/10 06:00
MHDA- 2016/03/30 06:00
PMCR- 2016/06/07
CRDT- 2015/12/10 06:00
PHST- 2014/07/19 00:00 [received]
PHST- 2015/01/19 00:00 [accepted]
PHST- 2015/12/10 06:00 [entrez]
PHST- 2015/12/10 06:00 [pubmed]
PHST- 2016/03/30 06:00 [medline]
PHST- 2016/06/07 00:00 [pmc-release]
AID - 10.4088/JCP.14m09395 [doi]
PST - ppublish
SO  - J Clin Psychiatry. 2015 Nov;76(11):1556-63. doi: 10.4088/JCP.14m09395.